|
COPYRIGHT 2005 Business Wire
FRANKLIN LAKES, N.J. -- ReGen Biologics, Inc. (OTC:RGBI) an orthopedic products company that develops, manufactures, and markets innovative tissue growth and repair products, announced today an exclusive distribution agreement with Xmedica to market the ReGen(R) CMI(TM) in Italy. The CMI is a type I collagen implant designed to facilitate growth of new tissue to replace removed or missing meniscus tissue in the human knee. Xmedica will also market ReGen's SharpShooter(R) Tissue Repair System on a non-exclusive...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
